Bio-Me

Bio-Me is a commercial-stage microbiome analytics company based in Oslo, Norway. Its proprietary qPCR-based PMP™ platform addresses key limitations of next-generation sequencing (NGS) by offering faster turnaround, higher precision, lower cost, and simplified bioinformatics, making large-scale, routine microbiome analysis feasible. The company has successfully transitioned from a service provider to a diagnostics development partner, with active programs in women's health, oncology, and inflammatory diseases, supported by strategic partnerships with biotechs and participation in EU consortia. Leadership has recently been bolstered with a Co-CEO structure to drive capitalization and commercial growth.

Proprietary Precision Microbiome Profiling (PMP™) platform, a high-throughput, quantitative PCR (qPCR)-based system for rapid, accurate, and reproducible microbiome analysis down to species and strain level.

Bio-Me competes with broad NGS service providers (e.g., Illumina, Eurofins) and specialized microbiome sequencing companies. Its primary differentiation is the shift from NGS to targeted qPCR for clinical applications, emphasizing speed, cost, and reproducibility. It also faces competition from large diagnostic firms developing their own microbiome-based tests.